Summary
The ASPECT-cIAI trial demonstrates high clinical cure rates, similar to those of meropenem, with ceftolozane/tazobactam plus metronidazole in patients with complicated intra-abdominal infections in a European population. In addition, a post hoc analysis shows similar outcomes between patients who are nonobese and obese.
- ceftolozane/tazobactam
- metronidazole
- meropenem
- complicated intra-abdominal infection
- ASPECT-cIAI
- European population
- obesity
- infectious diseases clinical trials
- emerging therapies
- © 2015 SAGE Publications
Tools
Subset Analyses of ASPECT-cIAI: Ceftolozane/Tazobactam Effective in cIAIs
Permalink:
Table of contents
Cited By...
- No citing articles found.